Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On August 5, 2026, the Cambridge, Massachusetts-based biotech (NASDAQ: ENVB) released new preclinical data it says strengthens the argument that its lead candidate, EB-003, can do exactly that. The post Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High appeared first on Microdose.